Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 15/20 | 1.00 |
| ▸ | CACNA1G | O43497 | 5/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.61 |
| ▸ | GAA | P10253 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | GLA | P06280 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8230047 | 0.88 | HTR3A (1.00) | HTR3ACACNA1GALDH1A1KDM4EHSD17B10 | |
| SCHEMBL8230066 | 0.85 | HTR3A (1.00) | HTR3ACACNA1GALDH1A1KDM4EHSD17B10 | |
| SCHEMBL8230914 | 0.83 | HTR3A (1.00) | HTR3ACACNA1GALDH1A1KDM4EHSD17B10 | |
| SCHEMBL8230911 | 0.81 | HTR3A (1.00) | HTR3ACACNA1GALDH1A1KDM4EHSD17B10 | |
| SCHEMBL8222478 | 0.80 | HTR3A (1.00) | HTR3ACACNA1GALDH1A1KDM4EHSD17B10 | |
| SCHEMBL8227995 | 0.80 | HTR3A (1.00) | HTR3ACACNA1GALDH1A1KDM4EHSD17B10 | |
| SCHEMBL8222473 | 0.78 | HTR3A (1.00) | HTR3ACACNA1GALDH1A1KDM4EHSD17B10 | |
| SCHEMBL8230918 | 0.77 | HTR3A (1.00) | HTR3ACACNA1GALDH1A1KDM4EHSD17B10 | |
| SCHEMBL4252448 | 0.76 | SMN1; SMN2 (0.66) | HTR3AALDH1A1KDM4EHSD17B10GAA | |
| SCHEMBL8227931 | 0.76 | HTR3A (1.00) | HTR3ACACNA1GALDH1A1KDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8748422-B2 | Pharmaceutical compositions containing quinazoline derivatives for treating as serotonin receptor antagonist | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2014-06-10 | — | — | US | disclosed |
| US-8748422-B2 | Pharmaceutical compositions containing quinazoline derivatives for treating as serotonin receptor antagonist | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2014-06-10 | — | — | US | disclosed |
| US-20090054433-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING QUINAZOLINE DERIVATIVES FOR TREATING AS SEROTONIN RECEPTOR ANTAGONIST | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2009-02-26 | — | — | US | disclosed |
| US-20090054433-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING QUINAZOLINE DERIVATIVES FOR TREATING AS SEROTONIN RECEPTOR ANTAGONIST | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054433-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING QUINAZOLINE DERIVATIVES FOR TREATING AS SEROTONIN RECEPTOR ANTAGONIST | HTR3A, HTR3B, HTR3E | HTR3A 1/4885CACNA1G 1559/4885ALDH1A1 3475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.